-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the primary analysis of the INSIGHT trial (NCT01982955; median follow-up: 21.
In the primary analysis of the INSIGHT trial (NCT01982955; median follow-up: 21.
At the recent AACR2022 meeting, experts from the University of Malaya School of Medicine and other institutions jointly reported the final analysis results of the INSIGHT trial
Patients with EGFR-mutant (T790M-negative) NSCLC and anti-EGFR resistance, MET gene copy number (GCN) ≥ 5 by FISH and/or MET:CEP7 ≥ 2 and/or MET IHC 2+/3+, were randomized to receive terpoor Titinib 500 mg (450 mg active molecule) + Gefitinib 250 mg QD or CTX
Patients with EGFR-mutant (T790M-negative) NSCLC and anti-EGFR resistance, MET gene copy number (GCN) ≥ 5 by FISH and/or MET:CEP7 ≥ 2 and/or MET IHC 2+/3+, were randomized to receive terpoor Titinib 500 mg (450 mg active molecule) + Gefitinib 250 mg QD or CTX
RESULTS: Among 19 of 55 randomized patients (34.
Efficacy and safety in patients with MET amplification
Overall, compared with CTX, tepotinib plus gefitinib improved PFS (HR=0.
Overall, compared with CTX, tepotinib plus gefitinib improved PFS (HR=0.
In conclusion, in patients with EGFR-mutant NSCLC with MET amplification, tepotinib plus gefitinib significantly improved PFS and OS
source:
source:https://#!/10517/presentation/20277
https://#!/10517/presentation/20277 https://#!/10517/presentation/20277Leave a comment here